NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded Pacific Biosciences to a Neutral rating after the next-generation sequencing company announced better than expected placements of its instruments.

The investment bank upgraded PacBio from its previous rating of Underweight, and raised the price target on its shares to $3.10 from $2.00.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.